The Prognostic Value of Intermedin in Patients with Breast Cancer

Table 1

The factors associated with mortality and adverse events during 5-year follow-up.

Characteristics	Mortality			Adverse event
	Yes	No	value	Yes	No	value
Number	60	192		88	164
Age			0.170			0.352
≤44 y	23 (38.3%)	93 (48.4%)		37 (42.0%)	79 (48.2%)
≥45 y	37 (61.7%)	99 (51.6%)		51 (58.0%)	85 (51.8%)
Menopausal status			0.030			0.010
Premenopausal	30 (50.0%)	126 (65.6%)		45 (51.1%)	111 (67.7%)
Postmenopausal	30 (50.0%)	66 (34.4%)		43 (48.9%)	53 (32.3%)
Tumor size			0.001			0.005
<2 cm	22 (36.7%)	117 (60.9%)		38 (43.2%)	101 (61.6%)
≥2 cm	38 (63.3%)	75 (39.1%)		50 (56.8%)	63 (38.4%)
Tumor-mode-metastasis stage			0.003			0.011
I, II	33 (55.0%)	144 (75.0%)		53 (60.2%)	124 (75.6%)
III	27 (45.0%)	48 (25.0%)		35 (39.8%)	40 (24.4%)
Lymph node status			<0.001			<0.001
Negative	21 (35.0%)	124 (64.6%)		36 (40.9%)	109 (66.5%)
Positive	39 (65.0%)	68 (35.4%)		52 (59.1%)	55 (33.5%)
Histologic grade			<0.001			0.002
I, II	22 (36.7%)	120 (62.5%)		38 (43.2%)	104 (63.4%)
III	38 (63.3%)	72 (37.5%)		50 (56.8%)	60 (36.6%)
Nuclear grade			0.001			0.007
I, II	22 (36.7%)	116 (60.4%)		38 (43.2%)	100 (61.0%)
III	38 (63.3%)	76 (39.6%)		50 (56.8%)	64 (39.0%)
Estrogen receptor status			<0.001			0.001
Positive	21 (35.0%)	122 (63.5%)		37 (42.1%)	106 (64.6%)
Negative	39 (65.0%)	70 (36.5%)		51 (57.9%)	58 (35.4%)
Progesterone receptor status			0.003			0.015
Positive	23 (38.3%)	115 (60.0%)		39 (44.3%)	99 (60.4%)
Negative	37 (61.7%)	77 (40.0%)		49 (55.7%)	65 (39.6%)
Intermedin			<0.001			<0.001
Low intermedin level	15 (25.0%)	135 (70.3%)		26 (29.6%)	124 (75.6%)
High intermedin level	45 (75.0%)	57 (29.7%)		62 (70.4%)	40 (24.4%)

Variables were presented as counts (percentage). Intergroup comparisons were completed by Chi-square test or Fisher exact test.